Stock listing

NASDAQ:AVBP ArriVent BioPharma, Inc. Stock

Home listing (NASDAQ) of ArriVent BioPharma, Inc.

Follow ArriVent BioPharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AVBP

$10.52 USD -0.38 (-3.5%)

Close on Nov 20, 2026

Past year -47.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.38 – $11.35 USDNov 20, 2026
Volume
1.05M sharesNov 20, 2026
Market cap
$544.1M USDAt the close on Nov 20, 2026 · price × 51.72M shares outstanding
52-week range
$10.33 – $35.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$24.59M USDMedian day 817,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ArriVent BioPharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AVBP · Home$10.52 USD-0.38 (-3.5%)1,053,366$10.93$11.35$10.38$10.90Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVBP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.52-0.38-3.5%$10.93$11.35$10.381,053,366
$10.90+0.21+2.0%$10.42$11.11$10.332,696,657
$10.69-0.87-7.5%$11.57$11.87$10.50863,852
$11.56-1.45-11.1%$12.86$13.14$11.55644,206
$13.01-0.06-0.5%$13.00$13.24$12.59616,140
$13.07-0.435-3.2%$13.55$13.60$12.89793,945
$13.51+0.015+0.1%$13.62$13.91$13.38910,925
$13.49-0.67-4.7%$14.25$15.05$13.21776,294
$14.16+0.52+3.8%$13.86$14.60$13.50905,949
$13.64+1.41+11.5%$12.40$13.88$12.001,400,448
$12.23-1.26-9.3%$13.39$13.50$12.181,101,682
$13.49+0.47+3.6%$13.39$13.57$12.471,624,627
$13.02-0.33-2.5%$13.47$13.94$13.011,226,259
$13.35-1.52-10.2%$14.89$14.98$13.261,237,292
$14.87-1.08-6.8%$15.78$16.17$14.331,194,900
$15.95+0.22+1.4%$15.87$16.42$15.73658,000
$15.73+0.33+2.1%$15.67$15.89$15.20990,000
$15.40+0.04+0.3%$15.45$15.69$15.001,582,000
$15.36-5.64-26.9%$18.14$18.16$14.785,946,900
$21.00+1.80+9.4%$19.00$21.23$18.183,277,900
$19.20+0.08+0.4%$18.93$19.68$18.78843,700
$19.12+0.27+1.4%$19.07$19.44$18.681,489,200
$18.85+0.91+5.1%$17.94$18.98$17.57817,800
$17.94+1.28+7.7%$16.82$18.14$16.731,013,200
$16.66-0.13-0.8%$16.86$17.23$16.491,334,000
$16.79+0.59+3.6%$16.40$16.91$15.97814,900
$16.20+0.11+0.7%$16.06$16.62$15.261,589,100
$16.09-0.37-2.2%$16.28$16.72$15.951,968,300
$16.46-0.27-1.6%$16.57$16.78$16.261,335,400
$16.73+0.02+0.1%$16.59$17.76$16.491,731,100
$16.71-0.18-1.1%$16.62$16.91$15.782,154,200
$16.89+1.80+11.9%$15.25$17.35$14.974,332,600
$15.09-13.37-47.0%$12.09$15.79$11.3619,742,400
$28.46+0.19+0.7%$28.00$28.70$27.02494,800
$28.27-0.66-2.3%$29.26$29.33$27.80507,600
$28.93-1.35-4.5%$29.99$30.64$28.81591,800
$30.28+0.74+2.5%$29.69$30.90$29.65712,500
$29.54+0.24+0.8%$29.30$30.05$28.80780,000
$29.30+0.85+3.0%$28.38$29.90$28.021,016,600
$28.45-1.65-5.5%$30.16$30.55$28.43653,200
$30.10-0.20-0.7%$29.94$30.51$29.24609,000
$30.30-0.02-0.1%$30.32$31.49$29.841,206,000
$30.32+0.58+2.0%$30.22$30.50$29.56389,100
$29.74+0.84+2.9%$29.17$31.16$28.20937,000
$28.90+0.54+1.9%$29.00$29.64$28.621,238,500
$28.36+0.71+2.6%$28.24$28.45$27.84456,400
$27.65-0.32-1.1%$28.15$28.31$27.28379,400
$27.97-0.60-2.1%$28.51$28.75$27.70337,300
$28.57-0.43-1.5%$29.10$29.83$28.40538,300
$29.00+0.30+1.0%$29.16$29.21$28.151,132,000
$28.70-1.09-3.7%$29.33$30.53$28.54564,200
$29.79-0.49-1.6%$30.02$30.26$29.40280,100
$30.28-0.67-2.2%$30.57$31.40$30.02722,000
$30.95-0.08-0.3%$30.79$31.45$30.60182,400
$31.03+0.52+1.7%$30.58$31.39$30.22465,400
$30.51+0.36+1.2%$30.33$30.79$29.60423,900
$30.15+0.10+0.3%$30.10$30.33$29.70356,100
$30.05-0.12-0.4%$29.94$30.26$29.35369,600
$30.17-0.83-2.7%$30.53$31.37$29.75353,500
$31.00-0.14-0.4%$30.79$31.77$30.24300,000
$31.14-0.21-0.7%$31.21$31.41$30.11433,800
$31.35+3.09+10.9%$28.64$31.52$28.64961,653
$28.26-0.86-3.0%$29.02$29.02$28.05225,594
$29.12-0.06-0.2%$29.45$29.77$28.95304,800
$29.18-0.84-2.8%$29.73$29.81$28.64406,300
Ticker
NASDAQ:AVBP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All ArriVent BioPharma, Inc. news

ArriVent BioPharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 34 in all · newest Nov 9, 2026 · oldest 2024
Decks
4 decks · latest August 2026

Where ArriVent BioPharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AVBP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AVBPBOATSUnited StatesUSD

Valuation

EV/sales 30.2× against a median of 44.8×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$151.2M USD
P/E
Loss
EV/sales
30.2×
EV/EBITDA
Negative EBITDA
Price/book
1.4×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.18

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ArriVent BioPharma, Inc. · NASDAQ:AVBPUS$544.1MUS$151.2Mn/a30.2×n/a1.4×n/a0.0×1.18
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$572.0MUS$430.9Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.4MUS$231.7Mn/a761×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.9MUS$613.6M14.5×4.5×22.9×2.6×28.0%0.8×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Abbisko Cayman Limited · HKEX:2256US$519.0MUS$228.1Mn/an/an/a1.6×n/a0.2×n/a
Median of the othersUS$557.6MUS$322.2M14.5×44.8×22.9×2.1×−90.3%0.0×1.43

Forecasts

11 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
26.10 USD · Analysts' mean
EPS, year to Dec 2026
-4.05 · 9 analysts
Revenue, year to Dec 2026
5M · 5 analysts

Team and board

Officers

OfficerRole
Zhengbin YaoChairman, Chief Executive Officer
Winston KungChief Financial Officer
Robin LaChapelleChief Operating Officer
James KastenmayerGeneral Counsel
Brent RiceChief Commercial Officer
Yang WangChief Technology Officer

Board

DirectorRole
Zhengbin YaoChairman, Chief Executive Officer
Chris NoletDirector
James HealyDirector
John HohnekerDirector
Kristine PetersonLead Independent Director
Merdad ParseyDirector
Stuart LutzkerDirector

Events

Next results
Mar 8, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−4.7%
Q2 2026Aug 12, 2026−4.4%
Q1 2026May 11, 2026 · After close−0.2%
Q4 2025Mar 26, 2026−5.8%
Q3 2025Nov 10, 2025 · Before open+3.1%
Q2 2025Aug 11, 2025 · Before open−3.3%
Q1 2025May 12, 2025 · Before open−0.8%
Q4 2024Mar 3, 2025−7.0%
Q3 2024Nov 14, 2024 · Before open−11.9%
Q2 2024Aug 14, 2024 · After close−0.4%
All 12 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open+0.6%
Q4 2023Mar 28, 2024 · After close+2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck21 slidesAugust 2026
Investor Presentation (June 2025)Investor deck25 slidesJun 23, 2025
Technical Presentation (September 2024)Technical13 slidesSep 8, 2024
European Lung Cancer Congress 2022Conference12 slidesMar 18, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: US$75M · US$19.5 a share · Goldman Sachs & Co. LLC +7
Dealers: Goldman Sachs & Co. LLC (co-lead), Citigroup (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Oppenheimer & Co., B. Riley Securities, H.C. Wainwright & Co., Jones
Use of proceeds: Support activities for firmonertinib and other pipeline programs, working capital and general corporate purposes
Jul 1, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Jan 25, 2024.

Price
US$18.00 a share
Shares offered
9,722,222 shares of common stock
Offering size
US$175 million
Underwriters' option
Up to 1,458,333 more shares
Listing
AVBP on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Citigroup, LifeSci Capital · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 25, 2023
Filed publiclyJan 5, 2024
Amended twiceNewest Jan 23, 2024
Shares registered with an exchangeJan 23, 2024
Declared effective by the SECJan 25, 2024
Final prospectus, with the priceJan 26, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Revenue0000
Research and development153.4M153.4M79.0M79.0M64.9M64.9M30.4M6.43M
Selling, general and administrative24.2M15.3M9.71M6.47M3.02M
Operating income-177.5M-177.5M-94.3M-94.3M-74.6M-74.6M-36.9M-8.70M
Depreciation and amortization-3.03M3.03M36.9M11.6M
EBITDA-180.6M-174.5M02.90M
Income before tax-166.3M-80.5M-69.3M-36.9M-51.6M
Income tax-80.5M-36.9M-11.6M
Net income-166.3M-166.3M-80.5M-80.5M-69.3M-69.3M-36.9M-51.6M
Earnings per share, basic-4.32-4.32-2.56-2.56-32.38-2.17-1.10-40.44
Earnings per share, diluted-4.32-2.56-32.38

Balance sheet

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash and equivalents45.5M45.5M74.3M74.3M150.4M150.4M163.4M37.3M
Short-term investments267.3M267.3M144.6M144.6M0
Receivables60.0K500.0K761.0K500.0K250.0K
Inventory-240.0K
Current assets332.9M332.9M227.0M227.0M160.0M160.0M182.6M43.0M
Total assets333.2M333.2M274.9M274.9M163.1M163.1M182.8M43.0M
Accounts payable5.93M5.93M3.78M3.78M4.53M4.53M3.09M293.0K
Current liabilities25.9M25.9M17.3M17.3M11.6M11.6M8.36M1.82M
Total debt14.0K176.0K317.0K139.0K
Total liabilities25.9M25.9M17.3M17.3M11.8M11.8M8.37M1.82M
Shareholders' equity307.2M307.2M257.7M257.7M-153.2M151.3M174.5M41.2M
Shares outstanding42.5M38.5M33.7M31.5M2.75M32.0M33.5M1.28M

Cash flow

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash from operations-160.6M-160.6M-70.2M-70.2M-55.8M-55.8M-43.6M-12.6M
Capital spending00000
Free cash flow-160.6M-70.2M-55.8M-43.6M-12.6M
Cash from investing-71.2M-71.2M-192.5M-192.5M-40.0M
Cash from financing203.1M203.1M186.6M186.6M42.9M42.9M169.7M89.9M
Change in cash-28.8M-28.8M-76.1M-76.1M-13.0M-13.0M126.1M37.3M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
8-K · Current reportOct 6, 2026Current reportSEC
All 162 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
8-K · Current reportMay 11, 2026Current reportSEC
424B5 · ProspectusMay 11, 2026Offer documentSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportMar 17, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2025Big-stake noticeSEC
8-K · Current reportSep 9, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportJul 21, 2025Current reportSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
424B5 · ProspectusJul 2, 2025Offer documentSEC
8-K · Current reportJul 2, 2025Material contractSEC
424B5 · ProspectusJul 1, 2025Offer documentSEC
8-K · Current reportJun 23, 2025Current reportSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
8-K · Current reportApr 28, 2025Management or board changeSEC
8-K · Current reportMar 13, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 3, 2025Offer documentSEC
8-K · Current reportMar 3, 2025ResultsSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
S-3ASR · Registration statementFeb 3, 2025Offer documentSEC
8-K · Current reportJan 21, 2025Material contractSEC
SC 13G · Big-stake noticeDec 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
4 · Change in ownershipSep 23, 2024Insider tradeSEC
8-K · Current reportSep 9, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K/A · Current report, amendedJul 9, 2024Management or board changeSEC
8-K/A · Current report, amendedJul 9, 2024Management or board changeSEC
8-K · Current reportJun 5, 2024Material contractSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 16, 2024Management or board changeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 23, 2024Insider tradeSEC
8-K · Current reportApr 22, 2024Management or board changeSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 2, 2024Offer documentSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
8-K · Current reportJan 30, 2024Current reportSEC
SEC STAFF LETTERJan 30, 2024Other filingsSEC
4 · Change in ownershipJan 29, 2024Insider tradeSEC
4 · Change in ownershipJan 29, 2024Insider tradeSEC
424B4 · ProspectusJan 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 26, 2024Other filingsSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringJan 25, 2024Offer documentSEC
CERT · Exchange's certificate of listingJan 25, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 23, 2024Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 22, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 22, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 12, 2024Other filingsSEC
CORRESP · Letter to the SECJan 11, 2024Other filingsSEC
S-1 · Registration statementJan 5, 2024Offer documentSEC
DRSLTR · Letter to the SEC with a draftDec 5, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedDec 5, 2023Offer documentSEC
UPLOAD · Letter from the SECNov 15, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftOct 31, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedOct 31, 2023Offer documentSEC
UPLOAD · Letter from the SECOct 18, 2023Other filingsSEC
SEC STAFF LETTEROct 13, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftOct 4, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedOct 4, 2023Offer documentSEC
UPLOAD · Letter from the SECSep 27, 2023Other filingsSEC
DRS · Draft registration statementAug 25, 2023Offer documentSEC
DDec 29, 2022Other filingsSEC
D/AFeb 14, 2022Other filingsSEC
DJun 23, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ArriVent BioPharma, Inc.’s releases · as of Nov 5, 2026

Common shares
51,723,074
Fully diluted
51,723,074

Fully diluted

LineSharesAs of
Common shares51,723,074Nov 5, 2026

Share count over time

CountShares
Nov 5, 202651,723,074
Sep 30, 202651,212,170

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Montanova Capital, LLC4.93M9.5%US$149M+410KNov 16, 2026
Infinitum Asset Management, LLC4.52M8.7%US$137M+85,539Nov 16, 2026
Hhlr Advisors, LTD.3.93M7.6%US$119MNo changeNov 16, 2026
BlackRock3.41M6.6%US$103M+157KNov 13, 2026
Orbimed Advisors LLC3.03M5.9%US$91.7MNo changeNov 16, 2026
Fidelity2.97M5.7%US$89.8M+188KNov 10, 2026
Vanguard2.74M5.3%US$83.1M+343KNov 13, 2026
Octagon Capital Advisors LP2.14M4.1%US$64.8M+170KNov 16, 2026
Vivo Capital, LLC1.79M3.5%US$54.1M+105KNov 13, 2026
State Street1.76M3.4%US$53.4M+70,113Nov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Sofinnova Investments, Inc.1.7M3.3%US$51.4MNo changeNov 16, 2026
General Catalyst Group Management, LLC1.49M2.9%US$45.3MNo changeNov 16, 2026
Logos Global Management LP1.35M2.6%US$40.9M+350KNov 19, 2026
Novo Holdings A/S1.18M2.3%US$35.6M−325KNov 16, 2026
Goldman Sachs1.11M2.1%US$33.5M+253KNov 16, 2026
Bank of America1.07M2.1%US$32.4M+896KNov 16, 2026
Geode Capital1.06M2.0%US$32M+82,592Nov 6, 2026
D. E. Shaw & Co., Inc.908K1.8%US$27.5M+36,464Nov 16, 2026
Adage Capital Partners Gp, L.L.C.686K1.3%US$20.8MNewNov 16, 2026
HSG Holding Ltd663K1.3%US$20.1MNo changeNov 13, 2026
UBS569K1.1%US$17.2M+119KNov 16, 2026
Millennium509K0.98%US$15.4M+69,847Nov 16, 2026
Balyasny Asset Management L.P.503K0.97%US$15.2M+108KNov 16, 2026
Point72 Asset Management, L.P.493K0.95%US$14.9M−73,591Nov 16, 2026
Foresite Capital Management VI LLC490K0.95%US$14.8M+189KNov 16, 2026
Seven Fleet Capital Management LP451K0.87%US$13.7M+205KNov 16, 2026
Schwab366K0.71%US$11.1M+71,514Nov 16, 2026
Northern Trust349K0.67%US$10.6M+16,030Nov 16, 2026
Dimensional325K0.63%US$9.84M+113KNov 4, 2026
Ameriprise313K0.61%US$9.48M−68,435Nov 16, 2026
E Fund Management Co., Ltd.278K0.54%US$8.41M+168KNov 12, 2026
Acuta Capital Partners, LLC171K0.33%US$5.17M−47,801Nov 16, 2026
Morgan Stanley167K0.32%US$5.06M−22,819Nov 13, 2026
Woodline Partners LP153K0.30%US$4.64M+5,690Nov 16, 2026
Wellington134K0.26%US$4.05M+32,966Nov 16, 2026
Trexquant Investment LP119K0.23%US$3.61M+47,425Nov 16, 2026
Algert Global LLC108K0.21%US$3.26MNewNov 17, 2026
Nomura105K0.20%US$3.18M−49,722Nov 16, 2026
BNY103K0.20%US$3.13M−450Nov 5, 2026
Nuveen102K0.20%US$3.09M−5,842Nov 10, 2026
KVP Capital Advisors, LP102K0.20%US$3.09MNo changeNov 16, 2026
SummitTX Capital, L.P.102K0.20%US$3.09MNewNov 16, 2026
Affinity Asset Advisors, LLC100K0.19%US$3.03M−25,000Nov 13, 2026
Vestal Point Capital, LP100K0.19%US$3.03MNewNov 16, 2026
Hrt Financial LP94,6540.18%US$2.87M−26,570Nov 13, 2026
Sectoral Asset Management Inc87,3430.17%US$2.64M+8,300Nov 13, 2026
Barclays82,4520.16%US$2.5M+11,482Nov 6, 2026
Jump Financial, LLC81,0670.16%US$2.45M+51,423Nov 13, 2026
Squarepoint Ops LLC73,1410.14%US$2.21M+55,597Nov 9, 2026
Assenagon Asset Management S.A.67,0950.13%US$2.03MNewOct 15, 2026

This page holds 50 of 146 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Select Biotechnology Portfolio1.44M2.8%US$43.6M−240KMay 31, 2026
Vanguard Total Stock Market Index Fund1.34M2.6%US$46.5M+184KJun 30, 2026
iShares Russell 2000 ETF985K1.9%US$34.2M+210KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF880K1.7%US$30.6M+179KJun 30, 2026
Fidelity Small Cap Index Fund415K0.80%US$12.4M+95,687Jul 31, 2026
Vanguard Extended Market Index Fund397K0.77%US$13.8M+59,263Jun 30, 2026
iShares Russell 2000 Growth ETF350K0.68%US$12.2M+87,454Jun 30, 2026
Fidelity Growth Company Fund324K0.63%US$9.81MNo changeMay 31, 2026
Fidelity Small Cap Growth Fund299K0.58%US$8.91MNo changeJul 31, 2026
iShares Biotechnology ETF230K0.45%US$8.01M+29,245Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Russell 2000 Index Fund166K0.32%US$5.02M+19,417May 31, 2026
Fidelity Extended Market Index Fund158K0.31%US$4.79M−13,071May 31, 2026
Fidelity Small Cap Growth K6 Fund149K0.29%US$4.44MNo changeJul 31, 2026
Schwab U.S. Small-Cap ETF147K0.28%US$4.45M−2,180May 31, 2026
iShares Micro-Cap ETF127K0.25%US$4.41M+45,767Jun 30, 2026
Schwab Small-Cap Index Fund92,0660.18%US$2.75M+21,232Jul 31, 2026
Fidelity Growth Company K6 Fund90,3350.17%US$2.73M−1,178May 31, 2026
Goldman Sachs Small Cap Equity Insights Fund87,6440.17%US$2.61M+24,804Jul 31, 2026
Fidelity Series Growth Company Fund69,5000.13%US$2.1M−10,600May 31, 2026
Master Small Cap Index Series67,4050.13%US$2.34M+17,448Jun 30, 2026
Vanguard Health Care Index Fund62,6260.12%US$1.9M+1,618May 31, 2026
Fidelity Total Market Index Fund59,3610.11%US$1.8MNo changeMay 31, 2026
Dimensional U.S. Small Cap ETF55,8580.11%US$1.67M+14,382Jul 31, 2026
U.S. Micro Cap Portfolio50,2980.10%US$1.5M+14,263Jul 31, 2026
Nuveen Small Cap Blend Index Fund50,2780.10%US$1.5M+11,892Jul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF49,0750.09%US$1.7M+1,088Jun 30, 2026
Fidelity Series Total Market Index Fund46,7510.09%US$1.42M+2,901May 31, 2026
ALPS Medical Breakthroughs ETF45,5630.09%US$1.38M+8,771May 31, 2026
Tema Oncology ETF42,7440.08%US$1.29M+2,001May 31, 2026
EQ/2000 Managed Volatility Portfolio41,1150.08%US$1.43M+6,998Jun 30, 2026
U.S. Small Cap Portfolio36,7140.07%US$1.09M+11,076Jul 31, 2026
Fidelity Small Cap Growth Index Fund35,5310.07%US$1.23M+11,020Jun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund35,0850.07%US$1.05M−9,423Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund30,4390.06%US$921K+3,442May 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares29,8030.06%US$889K−10,294Jul 31, 2026
Fidelity Nasdaq Composite Index Fund27,0560.05%US$819KNo changeMay 31, 2026
LVIP State Street Small-Cap Index Fund26,9000.05%US$935K+9,900Jun 30, 2026
Nuveen Equity Index Fund24,8570.05%US$741K+9,158Jul 31, 2026
Fidelity Nasdaq Composite Index ETF22,8390.04%US$691K−715May 31, 2026
EQ/Small Company Index Portfolio22,4700.04%US$781K+6,790Jun 30, 2026
Goldman Sachs Small Cap Value Insights Fund21,0910.04%US$629K+6,599Jul 31, 2026
Schwab Total Stock Market Index Fund20,2690.04%US$604KNo changeJul 31, 2026
Vanguard Balanced Index Fund19,8740.04%US$690KNo changeJun 30, 2026
Fidelity ZERO Total Market Index Fund19,5970.04%US$584K+3,108Jul 31, 2026
Vanguard Institutional Total Stock Market Index Fund19,2810.04%US$670K+3,596Jun 30, 2026
Small Cap Index Fund19,0560.04%US$662K+3,676Jun 30, 2026
Optimize Strategy Index ETF18,8510.04%US$655K−65Jun 30, 2026
Global X Russell 2000 ETF18,1200.04%US$540K+4,173Jul 31, 2026
Schwab U.S. Broad Market ETF18,0080.03%US$545KNo changeMay 31, 2026
EQ/AB Small Cap Growth Portfolio17,6100.03%US$612K+7,030Jun 30, 2026

This page holds 50 of 144 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
Infinitum Asset Management, LLC9.90%4.12MDec 31, 2025
Montanova Capital, LLC9.90%3.41MJun 30, 2025
Hillhouse Investment Management, Ltd.9.50%3.93MDec 31, 2025
BlackRock, Inc.6.80%3.18MJun 30, 2026
FMR LLC5.80%2.86MSep 30, 2026
ORBIMED ADVISORS LLC5.80%2.88MOct 6, 2026
HBM Healthcare Investments (Cayman) Ltd.5.40%2.2MOct 8, 2025
Vivo Opportunity, LLC5.00%2.47MOct 6, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Jan 25, 2024 – Jan 30, 2024 · Past
James Healy
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Jun 20, 2017 · Past); Natera, Inc. (Director · Jul 1, 2015 – Apr 25, 2025 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 7, 2022 · Past); Humanigen Inc (Director · Aug 10, 2012 – Apr 30, 2013 · Past); Hyperion Therapeutics Inc (Director · Jul 25, 2012 – May 7, 2015 · Past); Durata Therapeutics Inc (Director · Jul 18, 2012 – Jul 24, 2012 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jul 11, 2016 · Past); Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – May 17, 2013 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); InterMune Inc (Director · Dec 31, 2005 – Sep 29, 2014 · Past)
Director · Since at least Jan 25, 2024
Kristine Peterson
Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Oct 19, 2026); Immunocore Holdings plc (Non-Executive Director · Since at least Jan 2, 2024); Enanta Pharmaceuticals, Inc. (Director · Since at least Sep 11, 2017); EyePoint, Inc. (Director · Jun 27, 2017 – Feb 28, 2020 · Past); Paratek Pharmaceuticals Inc (Director · Mar 2, 2016 – Sep 21, 2023 · Past); ImmunoGen Inc (Director · Jan 30, 2012 – Feb 12, 2024 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jun 27, 2022 · Past)
Lead Independent Director · Since at least Apr 20, 2024
John Hohneker
Other companies: Curis, Inc. (Director · Since at least Dec 2, 2021); Carisma Therapeutics, Inc. (Director · Apr 1, 2024 – Jun 26, 2024 · Past); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past)
Director · Since at least May 16, 2024
Chris Nolet
Other companies: Jasper Therapeutics, Inc. (Director · Since at least Sep 24, 2021); PolarityTE Inc. (Director · Apr 6, 2020 – Jan 12, 2023 · Past); Viela Bio Inc (Director · Oct 2, 2019 – Mar 15, 2021 · Past); Revance Therapeutics, Inc. (Director · Jul 16, 2019 – Feb 4, 2025 · Past)
Director · Since at least Jan 25, 2024
Merdad Parsey
Other companies: Ardelyx, Inc. (Director · Since at least Apr 28, 2025); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jun 5, 2024 · Past); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past)
Director · Since at least Apr 28, 2025
Zhengbin Yao
Other companies: Alumis Inc. (Director · Since at least Jun 27, 2024); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Viela Bio Inc (Chief Executive Officer, Director · Oct 2, 2019 – Mar 13, 2021 · Past); Tanox Inc (Vice President of Research · Feb 15, 2006 – Nov 20, 2006 · Past)
Chairman, Chief Executive Officer · Since at least Jan 25, 2024
Bahija Jallal
Other companies: Immunocore Holdings plc (Chief Executive Officer · Since at least Jan 2, 2024); Elevance Health, Inc. (Director · Since at least Feb 1, 2018); Guardant Health, Inc. (Director · Apr 17, 2019 – Jun 15, 2022 · Past)
Director · Jan 25, 2024 – Jan 25, 2024 · Past
Winston Kung
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past)
Chief Financial Officer · Since at least Jan 25, 2024
James Kastenmayer
Other companies: Spyre Therapeutics, Inc. (General Counsel · Aug 23, 2022 – Feb 23, 2023 · Past); Viela Bio Inc (General Counsel · Jan 6, 2020 – Mar 15, 2021 · Past)
General Counsel · Since at least Jan 25, 2024
All 15 people
PersonSeat
Brent RiceChief Commercial Officer · Since at least Nov 10, 2025
Chris NoletDirector · Since at least Nov 4, 2026
Robin LaChapelleChief Operating Officer · Since at least Jan 25, 2024
Stuart LutzkerDirector · Since at least Jan 25, 2024
Yang WangChief Technology Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about ArriVent BioPharma, Inc.